Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$28.11

-0.83 (-2.87%)

11:44
04/09/18
04/09
11:44
04/09/18
11:44

Audentes Therapeutics management to meet with Wedbush.

Meeting to be held in Denver, CO on April 9 hosted by Wedbush.

  • 09

    Apr

BOLD Audentes Therapeutics
$28.11

-0.83 (-2.87%)

01/04/18
WEDB
01/04/18
NO CHANGE
Target $56
WEDB
Outperform
Audentes price target raised to $56 from $29 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Audentes Therapeutics to $56 saying the first dose cohort data from the Phase 1/2 trial for AT132 in X-Linked Myotubular Myopathy is "impressive." Treated patients experienced "significant and rapid improvements in several important functional metrics," Nierengarten tells investors in a research note. The analyst expects additional confirmatory updates throughout the year and keeps an Outperform on Audentes shares.
01/05/18
BMOC
01/05/18
NO CHANGE
Target $44
BMOC
Outperform
Audentes Therapeutics price target raised to $44 from $35 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Audentes Therapeutics to $44 after the company's release of initial AT132 Phase I/II data for the treatment of X-Linked Myotubular Myopathy. The analyst says the results offer a "proof of concept", adding he is encouraged by the improvements in neuromuscular and respiratory function from the treatment. Luchini keeps his Outperform rating on Audentes Therapeutics.
02/07/18
HCWC
02/07/18
NO CHANGE
Target $37
HCWC
Buy
Pompe could have 'major impact' on Audentes valuation, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay noted that the incidence of Pompe disease is materially higher than the diseases targeted by Audentes Therapeutics' existing clinical programs, which means the AT982 drug product is likely to have a major impact on valuation if it shows compelling clinical activity. After the company announced its selection of a clinical development candidate for its Pompe program and shared timeline expectations, Chattopadhyay reiterated his Buy rating and $37 price target on the stock.
02/12/18
MZHO
02/12/18
INITIATION
Target $26
MZHO
Neutral
Audentes Therapeutics initiated with a Neutral at Mizuho
Mizuho analyst Difei Yang started Audentes Therapeutics with a Neutral rating and $26 price target.

TODAY'S FREE FLY STORIES

12:05
08/20/18
08/20
12:05
08/20/18
12:05
General news
Fed's Bostic said the economy doesn't need as much stimulus as it did before »

Fed's Bostic said…

AVNW

Aviat Networks

$16.20

(0.00%)

12:04
08/20/18
08/20
12:04
08/20/18
12:04
Hot Stocks
Aviat Networks introduces online selling with new Aviat store »

Aviat Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFBK

Central Federal

$2.52

(0.00%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Central Federal announces 1-for-5.5 reverse stock split »

Central Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAHO

Tahoe Resources

$3.84

0.06 (1.59%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Tahoe Resources terminates approx. 200 additional Minera San Rafael employees »

Tahoe Resources regrets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$22.66

0.44 (1.98%)

12:01
08/20/18
08/20
12:01
08/20/18
12:01
Hot Stocks
Street Fight: Analysts split on Bloom Energy after IPO »

Several Wall Street…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$8.26

-0.46 (-5.28%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Comstock Resources falls -5.1% »

Comstock Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$46.80

-2.55 (-5.17%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Installed Building Products falls -5.3% »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Nov

LCI

Lannett

$5.55

-7.95 (-58.89%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Lannett falls -58.7% »

Lannett is down -58.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

CATM

Cardtronics

$37.25

0.08 (0.22%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Options
Second day of call buying in Cardtronics »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATV

Acorn International

$22.00

3.14 (16.65%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Acorn International rises 8.7% »

Acorn International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$23.96

2.43 (11.29%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Amneal Pharmaceuticals rises 11.5% »

Amneal Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 12

    Sep

CMCM

Cheetah Mobile

$10.85

1.75 (19.23%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Cheetah Mobile rises 19.5% »

Cheetah Mobile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PCG

PG&E

$45.05

-0.195 (-0.43%)

, EIX

Edison International

$69.44

-0.42 (-0.60%)

11:59
08/20/18
08/20
11:59
08/20/18
11:59
Periodicals
California's Dodd says securitization of PG&E liability mulled, Bloomberg says »

California Senator Bill…

PCG

PG&E

$45.05

-0.195 (-0.43%)

EIX

Edison International

$69.44

-0.42 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IMTE

Integrated Media Technology

$12.20

0.2 (1.67%)

11:58
08/20/18
08/20
11:58
08/20/18
11:58
Hot Stocks
Integrated Media unit enters distribution agreement with Ai Holdings »

Integrated Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$106.76

-0.82 (-0.76%)

11:57
08/20/18
08/20
11:57
08/20/18
11:57
Hot Stocks
Skype's end-to-end encrypted Private Conversations now available for all users »

Microsoft's Skype…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

TSLA

Tesla

$302.49

-2.84 (-0.93%)

11:55
08/20/18
08/20
11:55
08/20/18
11:55
Recommendations
Tesla analyst commentary  »

Tesla may be wise to try…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TSLA

Tesla

$302.35

-2.98 (-0.98%)

11:52
08/20/18
08/20
11:52
08/20/18
11:52
Periodicals
Tesla's lawyers believe SEC 'under pressure' to expdite probe, Gasparino tweets »

FBN's Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PX

Praxair

$157.81

1.86 (1.19%)

, LNEGY

Linde

$0.00

(0.00%)

11:51
08/20/18
08/20
11:51
08/20/18
11:51
Hot Stocks
EU approves proposed merger between Linde, Praxair »

The European Commission…

PX

Praxair

$157.81

1.86 (1.19%)

LNEGY

Linde

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$285.40

0.38 (0.13%)

11:50
08/20/18
08/20
11:50
08/20/18
11:50
Options
Continued interest in end of year call spreads in SPDR 500 Trust options »

Continued interest in end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
08/20/18
08/20
11:50
08/20/18
11:50
General news
Treasury's $96 B 3- and 6-month bill sale was ok »

Treasury's $96 B 3-…

XLU

Utilities SPDR

$54.43

-0.07 (-0.13%)

11:40
08/20/18
08/20
11:40
08/20/18
11:40
Options
Opening call write in SPDR Utility ETF »

Opening call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

IMNP

Immune Pharmaceuticals

$0.00

(0.00%)

11:36
08/20/18
08/20
11:36
08/20/18
11:36
Hot Stocks
Immune Pharmaceuticals granted Orphan Drug Designation for bertilimumab »

Immune Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

RIG

Transocean

$11.23

0.47 (4.37%)

11:30
08/20/18
08/20
11:30
08/20/18
11:30
Options
Notable call buyer in Transocean »

Notable call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.